TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28345432

Group type: EXPERIMENTAL
Intervention: Sildenafil citrate, 50 mg
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 26878553

Group type: EXPERIMENTAL
Intervention: 10-week structured exercise with a jaw mobilizing device (TheraBite® jaw device or Engström device)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 50
Study: 24865782

Group type: EXPERIMENTAL
Intervention: Revaclear high‐flux (A)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Helixone high‐flux (B)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Xevonta high‐flux (C)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Helixone low‐flux (D)
Number of subjects: 25
Study: 22311531

Group type: EXPERIMENTAL
Intervention: Cerebrolysin plus risperidone
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo (risperidone only)
Number of subjects: 109
Study: 20442354

Group type: EXPERIMENTAL
Intervention: Finasteride 1 mg orally daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Topical minoxidil
Number of subjects: 0
Study: 17850539

Group type: EXPERIMENTAL
Intervention: Short-term prevention regimens for menstrual migraine
Number of subjects: 0
Study: 15857519

Group type: EXPERIMENTAL
Intervention: Chlamydia Pneumoniae positive group (aCP‐IgG > 1:8)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (aCP‐IgG <or= 1:8)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both groups (CP positive and CTRL)
Number of subjects: 16
Study: 12450262

Group type: EXPERIMENTAL
Intervention: LQT1 patients (n = 7)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: LQT2 patients (n = 9)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (n = 33)
Number of subjects: 49
Study: 9933794

Group type: EXPERIMENTAL
Intervention: 60 mg/day of urapidil for 4 weeks
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Urapidil
Number of subjects: 149
Study: 7569017

Group type: EXPERIMENTAL
Intervention: Multiple fractions per day (MFD) with misonidazole
Number of subjects: 523

Group type: COMPARATOR
Intervention: Multiple fractions per day (MFD) without misonidazole
Number of subjects: 523

Group type: COMPARATOR
Intervention: Conventional fractionation
Number of subjects: 523
Study: 2179912

Group type: EXPERIMENTAL
Intervention: Continuous vacuum suction (VariDyne)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Intermittent spring type system (Hemovac)
Number of subjects: 126
Study: 157264

Group type: EXPERIMENTAL
Intervention: 5% benzoyl peroxide gel
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.05% retinoic acid cream
Number of subjects: 0
Study: 30528795

Group type: EXPERIMENTAL
Intervention: Kuchi‐kara Taberu (KT) index intervention
Number of subjects: 233

Group type: COMPARATOR
Intervention: Control group (before KT index intervention)
Number of subjects: 233
Study: 28218343

Group type: EXPERIMENTAL
Intervention: Robotic‐assisted gait training
Number of subjects: 16

Group type: COMPARATOR
Intervention: Physical therapy
Number of subjects: 16
Study: 25387428

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation applied to the trapezius muscle
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 100
Study: 25123060

Group type: EXPERIMENTAL
Intervention: DHA-O (2.4 g/day DHA and EPA in a 2.7:1 ratio)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Fish Oil (FO; 2.0 g/day DHA and EPA in a 0.7:1 ratio)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Corn oil/soy oil control
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: DHA-O
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: FO
Number of subjects: 93
Study: 22825363

Group type: EXPERIMENTAL
Intervention: Capsule Endoscopy (CE)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Angiography
Number of subjects: 60
Study: 19864409

Group type: EXPERIMENTAL
Intervention: Folic acid (1 mg/d)
Number of subjects: 672

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 672
Study: 17377120

Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg dexamethasone IV
Number of subjects: 60

Group type: COMPARATOR
Intervention: 2 mL saline
Number of subjects: 60
Study: 14593453

Group type: EXPERIMENTAL
Intervention: DOEScore
Number of subjects: 1256

Group type: COMPARATOR
Intervention: FOSTA, SOFSURF, ORAI score systems
Number of subjects: 1256
Study: 11810130

Group type: EXPERIMENTAL
Intervention: HES 200/0.5/6
Number of subjects: 9

Group type: COMPARATOR
Intervention: 4% albumin
Number of subjects: 9
Study: 9588451

Group type: EXPERIMENTAL
Intervention: Insulin response to a 75‐g oral glucose load in nonrelatives
Number of subjects: 88

Group type: COMPARATOR
Intervention: Insulin response to a 75‐g oral glucose load in relatives
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Multivariate analysis for insulin response in nonrelatives
Number of subjects: 88

Group type: COMPARATOR
Intervention: Multivariate analysis for insulin response in relatives
Number of subjects: 88
Study: 7979639

Group type: EXPERIMENTAL
Intervention: Propranolol 160 mg LA
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 2609241

Group type: EXPERIMENTAL
Intervention: PGE1 (60 micrograms i.v. infusion daily for 3 weeks)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Naftidrofuryl (600 mg daily for 3 weeks)
Number of subjects: 48
Study: 1098353

Group type: EXPERIMENTAL
Intervention: Brompheniramine maleate and phenylpropanolamine hydrochloride (Lunerin mite)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 31756536

Group type: EXPERIMENTAL
Intervention: Tandem autologous transplant (auto-auto)
Number of subjects: 710

Group type: COMPARATOR
Intervention: Autologous followed by reduced intensity allogeneic transplantation (auto-allo)
Number of subjects: 710

Group type: EXPERIMENTAL
Intervention: Allogeneic HCT
Number of subjects: 710
Study: 27469294

Group type: EXPERIMENTAL
Intervention: Short dental implants (6-8 mm)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Long dental implants (11 mm)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control group (non-diabetic)
Number of subjects: 87
Study: 26659936

Group type: EXPERIMENTAL
Intervention: 0.3% A/BPO
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: 0.1% A/BPO
Number of subjects: 252

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 252
Study: 22824858

Group type: EXPERIMENTAL
Intervention: Warm, humidified CO2 gas insufflation (37°C, 98% relative humidity)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Standard room temperature CO2 gas insufflation (20°C, 0% relative humidity)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Warm, humidified CO2 gas insufflation
Number of subjects: 190

Group type: COMPARATOR
Intervention: Standard room temperature CO2 gas insufflation
Number of subjects: 190
Study: 20848528

Group type: EXPERIMENTAL
Intervention: Inflammatory bowel disease (IBD) patients with active disease
Number of subjects: 422

Group type: COMPARATOR
Intervention: Chronic liver disease (CLD) patients
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: IBD patients with slight disease activity
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: IBD patients with moderate/severe disease activity
Number of subjects: 422

Group type: COMPARATOR
Intervention: General population (GP)
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: IBD patients in remission
Number of subjects: 422
Study: 18435187

Group type: EXPERIMENTAL
Intervention: Copper Seal (Group 1)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Chlorhexidine varnish (Group 2)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Copper Seal without removal (Group 3)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Negative control (Group 4)
Number of subjects: 56
Study: 16528645

Group type: EXPERIMENTAL
Intervention: Magnetic endoscope imaging (MEI)
Number of subjects: 120

Group type: COMPARATOR
Intervention: No MEI (Control group)
Number of subjects: 120
Study: 12777590

Group type: EXPERIMENTAL
Intervention: Fluoroquinolones (FQ)
Number of subjects: 525

Group type: COMPARATOR
Intervention: Control group (other antibiotics)
Number of subjects: 525
Study: 10711911

Group type: EXPERIMENTAL
Intervention: Olanzapine (5-20 mg)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Risperidone (4-10 mg)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Haloperidol (5-20 mg)
Number of subjects: 65
Study: 9059196

Group type: EXPERIMENTAL
Intervention: Command and information tape (n = 34)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Radio static (n = 34)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Both groups (command and information tape and radio static)
Number of subjects: 68
Study: 1422752

Group type: EXPERIMENTAL
Intervention: Doppler colour flow imaging (DCFI)
Number of subjects: 30
Study: 3919555

Group type: EXPERIMENTAL
Intervention: bepridil (400 mg once a day)
Number of subjects: 15
Study: 31169354

Group type: EXPERIMENTAL
Intervention: Silicone gel (Stratacel®; Stratpharma) applied twice a day for 7 days
Number of subjects: 10

Group type: COMPARATOR
Intervention: Petrolatum-based ointment applied twice a day for 7 days
Number of subjects: 10
Study: 29431785

Group type: EXPERIMENTAL
Intervention: Glucono‐delta‐lactone (GDL) 2000 mg day‐1
Number of subjects: 40
Study: 27352486

Group type: EXPERIMENTAL
Intervention: Penetration acupuncture at acupoints of GV and bladder meridian on head (Wuchu to Chengguang, Tongtian to Luoque, Shenting to Xinhui, Qianding to Baihui, Houding to Qiangjian)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Body acupuncture and conventional western medication (both groups)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Observation group (acupuncture)
Number of subjects: 110
Study: 25090820

Group type: EXPERIMENTAL
Intervention: Unsedated transnasal endoscopy (TNE)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Unsedated transoral endoscopy (TOE)
Number of subjects: 400
Study: 22013100

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy targeting normoglycemia (80‐110 mg/dl)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tolerating hyperglycemia up to 215 mg/dl
Number of subjects: 0
Study: 20502909

Group type: EXPERIMENTAL
Intervention: High myopes
Number of subjects: 66
Study: 17728050

Group type: EXPERIMENTAL
Intervention: Sildenafil as monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sildenafil in combination with SSRI (paroxetine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sildenafil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Topical anesthetics
Number of subjects: 0
Study: 15914256

Group type: EXPERIMENTAL
Intervention: Standardized physical therapy plus 4 music therapy sessions
Number of subjects: 65

Group type: COMPARATOR
Intervention: Standardized physical therapy alone
Number of subjects: 65
Study: 12022321

Group type: EXPERIMENTAL
Intervention: Muscle strengthening program
Number of subjects: 68

Group type: COMPARATOR
Intervention: Stretching program
Number of subjects: 68
Study: 10768630

Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone sodium succinate treatment
Number of subjects: 100

Group type: COMPARATOR
Intervention: N/A (Control group)
Number of subjects: 100
Study: 8829312

Group type: EXPERIMENTAL
Intervention: Melatonin (40 mg/day orally in the evening, starting 7 days prior to cytokine injection)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Cytokine alone (IL-2: 3 x 10(6) IU/day s.c. every day, 6 days/week for 4 weeks; TNF: 0.75 mg/day i.v. for 5 days)
Number of subjects: 116
Study: 1313875

Group type: EXPERIMENTAL
Intervention: 4.1 g daily fibre supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3881913

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Long-term Verapamil therapy
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 31344685

Group type: EXPERIMENTAL
Intervention: Vitamin D3 5000 IU daily
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 29901760

Group type: EXPERIMENTAL
Intervention: Leucine (LEU; 10 g milk protein with 3 g total l-leucine)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Whey Protein Isolate (WPI; 25 g WPI with 3 g l-leucine)
Number of subjects: 22
Study: 26118849

Group type: EXPERIMENTAL
Intervention: Neuromuscular training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Wearing an ankle brace
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined training and bracing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bracing or combined bracing and NM training
Number of subjects: 0
Study: 24845198

Group type: EXPERIMENTAL
Intervention: Incentive spirometry
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Acapella device
Number of subjects: 78
Study: 22177390

Group type: EXPERIMENTAL
Intervention: Online guided self-help program for BED
Number of subjects: 92

Group type: COMPARATOR
Intervention: Pure dietary subtype
Number of subjects: 92
Study: 19960492

Group type: EXPERIMENTAL
Intervention: Citalopram (CIT) with dose escalation (20-60 mg/day)
Number of subjects: 301
Study: 18728660

Group type: EXPERIMENTAL
Intervention: Lapatinib combined with capecitabine
Number of subjects: 0
Study: 15968676

Group type: EXPERIMENTAL
Intervention: Magnetization transfer weighted imaging using cerebrospinal fluid as intersubject normalization reference (MTCSF imaging)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Magnetization transfer ratio (MTR)
Number of subjects: 0
Study: 12891211

Group type: EXPERIMENTAL
Intervention: 3.5 g of fish oil daily for 12 weeks
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo oil daily for 12 weeks
Number of subjects: 84
Study: 10684161

Group type: EXPERIMENTAL
Intervention: Ferrous fumarate (60 mg elemental Fe) daily
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Ferrous fumarate (60 mg elemental Fe) intermittently (three times a week)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 203
Study: 9102018

Group type: EXPERIMENTAL
Intervention: Videoendoscopy-assisted saphena occlusion (VASO)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Crossectomy, dissection of perforating veins and occlusion of the saphena by endoscopic control
Number of subjects: 0
Study: 30217371

Group type: EXPERIMENTAL
Intervention: AZL-M 80 mg
Number of subjects: 2630

Group type: EXPERIMENTAL
Intervention: AZL-M/CLD 40/25 mg
Number of subjects: 2630

Group type: EXPERIMENTAL
Intervention: AZL-M/CLD 80/25 mg
Number of subjects: 2630
Study: 27169436

Group type: EXPERIMENTAL
Intervention: Community exercise program (year-long, at least twice per week, supervised by a case manager)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0
Study: 24646921

Group type: EXPERIMENTAL
Intervention: Weight-shift training (WST)
Number of subjects: 18
Study: 22659765

Group type: EXPERIMENTAL
Intervention: Topical gentamicin-collagen sponge plus standard of care
Number of subjects: 56

Group type: COMPARATOR
Intervention: Standard of care only (control group)
Number of subjects: 56
Study: 19920832

Group type: COMPARATOR
Intervention: XELOX
Number of subjects: 306
Study: 17584482

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MP) in the priming solution
Number of subjects: 30

Group type: COMPARATOR
Intervention: Zero-balance ultrafiltration (ZBUF) during CPB
Number of subjects: 30
Study: 15805350

Group type: COMPARATOR
Intervention: Comprehensive regional hospital-based parent education program about violent infant shaking, administered at the time of the child's birth.
Number of subjects: 94209

Group type: COMPARATOR
Intervention: Follow-up telephone interviews conducted 7 months after birth to assess parents' recall of the information.
Number of subjects: 94209
Study: 11960949

Group type: EXPERIMENTAL
Intervention: Inhalational anesthetic
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Fentanyl (0.5 microg/kg iv)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: End-tidal CO2 exceeding 50 Torr
Number of subjects: 37
Study: 9871429

Group type: EXPERIMENTAL
Intervention: Rifampin 600 mg orally once a day for 5 days, followed by 80 mg tamoxifen on the sixth day.
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Rifampin 600 mg orally once a day for 5 days, followed by 120 mg toremifene on the sixth day.
Number of subjects: 19

Group type: COMPARATOR
Intervention: N/A (placebo phase)
Number of subjects: 19
Study: 7610930

Group type: EXPERIMENTAL
Intervention: Oral 1,25(OH)2D (Rocaltrol) 0.5 microgram twice a day for 5 days
Number of subjects: 24
Study: 2694180

Group type: EXPERIMENTAL
Intervention: arbaprostil 10 mcg
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: arbaprostil 25 mcg
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: arbaprostil 50 mcg
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: arbaprostil 400 mcg
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: arbaprostil 1200 mcg
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: arbaprostil 1600 mcg
Number of subjects: 4
Study: 154747

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide plus sodium cromoglycate
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 31183766

Group type: EXPERIMENTAL
Intervention: Attendees of the breast cancer screening program
Number of subjects: 502

Group type: COMPARATOR
Intervention: Non-attendees of the breast cancer screening program
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Age over 61
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Receiving the invitation letter
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Intention to participate
Number of subjects: 502
Study: 30877042

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 28403412

Group type: EXPERIMENTAL
Intervention: Extrafascial catheter tip placement
Number of subjects: 70

Group type: COMPARATOR
Intervention: Intrafascial catheter tip placement
Number of subjects: 70
Study: 23532371

Group type: EXPERIMENTAL
Intervention: Cemented hemiprosthesis
Number of subjects: 134

Group type: COMPARATOR
Intervention: Non-cemented hemiprosthesis
Number of subjects: 134
Study: 21893693

Group type: EXPERIMENTAL
Intervention: Melatonin (MEL) 5 mg daily at bedtime
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 19352213

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 30076
Study: 17047538

Group type: EXPERIMENTAL
Intervention: 2-stage procedure (Group A)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 1-stage procedure (Group B)
Number of subjects: 24
Study: 14557857

Group type: EXPERIMENTAL
Intervention: Bolus-titrated therapy (flunitrazepam, clonidine, haloperidol adjusted as needed)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Infusion-titrated therapy (continuous infusion of flunitrazepam, clonidine, haloperidol)
Number of subjects: 44
Study: 11789278

Group type: EXPERIMENTAL
Intervention: Weikangfu granule (WKF)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Weisu granule (control)
Number of subjects: 61
Study: 9120151

Group type: EXPERIMENTAL
Intervention: High intensity S1 stimulation
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: High intensity S1 stimulation at HLRA
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: High intensity S1 stimulation at DCS
Number of subjects: 40

Group type: COMPARATOR
Intervention: Propranolol and autonomic blockade
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 40
Study: 8268342

Group type: EXPERIMENTAL
Intervention: Halofantrine (500 mg daily for 3 days)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Halofantrine (500 mg daily for 6 days)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Chloroquine (total dose of 1,500 mg over 3 days)
Number of subjects: 400
Study: 3804184

Group type: EXPERIMENTAL
Intervention: 20 mg nifedipine
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 29609656

Group type: EXPERIMENTAL
Intervention: Sexual health continuous quality improvement (CQI) program
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Action plan setting, Systems Assessment Tool, STRIVE coordinator role
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Dedicated funding for health promotion and service incentive payments
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: CQI program
Number of subjects: 41
Study: 27084926

Group type: EXPERIMENTAL
Intervention: Training by doing (actual performance)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Training by observing (observation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Post-training performance of a second sequence
Number of subjects: 0

Group type: COMPARATOR
Intervention: Post-training observation of a second sequence
Number of subjects: 0
Study: 25064389

Group type: EXPERIMENTAL
Intervention: Primary perineal wound closure with neo-adjuvant (chemo)radiotherapy
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Extralevator approach
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Intra-operative perforation
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Persistent presacral sinus
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Perineal hernia
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Perineal wound complications
Number of subjects: 136
Study: 22419422

Group type: EXPERIMENTAL
Intervention: Wet cupping combined with dietary advice
Number of subjects: 126

Group type: COMPARATOR
Intervention: Dietary advice only (Control)
Number of subjects: 126
Study: 20728227

Group type: EXPERIMENTAL
Intervention: Levobupivacaine with epinephrine
Number of subjects: 20

Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 20
Study: 19062725

Group type: EXPERIMENTAL
Intervention: Docetaxel plus epirubicin (TE)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Docetaxel plus cisplatin (TP)
Number of subjects: 88
Study: 17012871

Group type: EXPERIMENTAL
Intervention: PRP-T/HBV10
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PRP-OMPC/HBV15
Number of subjects: 60

Group type: COMPARATOR
Intervention: Licensed vaccine (DTaP-IPV//PRP-T)
Number of subjects: 60
Study: 11901037

Group type: EXPERIMENTAL
Intervention: Distal embolic protection device
Number of subjects: 801

Group type: COMPARATOR
Intervention: Conventional 0.014-inch angioplasty guidewire (control group)
Number of subjects: 801